Neeland IJ, Lim S, Tchernof A, Gastaldelli A, Rangaswami J, Ndumele CE, et al. Metabolic syndrome. Nat Rev Dis Primers 2024; 10(1):77.

Byrne CD, Targher G. MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome? M&TOD 2024; 4(2):10.

Chew NWS, Ng CH, Tan DJH, Kong G, Lin C, Chin YH, et al. The global burden of metabolic disease: data from 2000 to 2019. Cell Metab 2023; 35(3):414.

Wong RJ. Epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD). M&TOD 2024; 4(4):35.

Liu H, Wang S, Wang J, Guo X, Song Y, Fu K, et al. Energy metabolism in health and diseases. Signal Transduct Target Ther 2025; 10(1):69.

Mlynarska E, Czarnik W, Dzieza N, Jedraszak W, Majchrowicz G, Prusinowski F, et al. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. Int J Mol Sci 2025; 26(3):1094.

Liu Z, Zhang Y, Graham S, Wang X, Cai D, Huang M, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol 2020; 73(2):263-76.

Mitten EK, Baffy G. Mechanobiology in the development and progression of nonalcoholic fatty liver disease: an updated review. Metab Target Organ Damage 2023; 3(1):2.

Cruz-Cruz I, Bernate-Obando G, Larque C, Escalona R, Pinto-Almazan R, Velasco M. Early effects of metabolic syndrome on ATP-sensitive potassium channels from rat pancreatic beta cells. Metabolites 2022; 12(4):365.

Dong XC, Chowdhury K, Huang M, Kim HG. Signal transduction and molecular regulation in fatty liver disease. Antioxid Redox Signal 2021; 35(9):689-717.

Visuthranukul C, Kwanbunbumpen T, Chongpison Y, Chamni S, Panichsillaphakit E, Uaariyapanichkul J, et al. The impact of dietary fiber as a prebiotic on inflammation in children with obesity. Foods 2022; 11(18):2856.

Harshfield EL, Fauman EB, Stacey D, Paul DS, Ziemek D, Ong RMY, et al. Genome-wide analysis of blood lipid metabolites in over 5000 south Asians reveals biological insights at cardiometabolic disease loci. BMC Med 2021; 19(1):232.

Huang Z, Sun A. Metabolism, inflammation, and cardiovascular diseases from basic research to clinical practice. Cardiol Plus 2023; 8(1):4-5.

Wang Z. The entropy perspective on human illness and aging. Engineering 2022; 9(2):22-6.

Guo HH, Shen HR, Wang LL, Luo ZG, Zhang JL, Zhang HJ, et al. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. Biomed Pharmacother 2023;163:114754.

Gao TL, Guo HH, Jiang JD. Neg-entropy mechanism as a target for natural medicines. Engineering 2024; 38(7):11-2.

Guo HH, Gao TL, Ma XL, Tie C, Jiang JD. Application of bio-entropy in drug evaluation. Chin Pharm J 2025; 60(3):209-13 [Chinese].

Lin YH, Liao YY, Yeh CK, Yang KC, Tsui PH. Ultrasound entropy imaging of nonalcoholic fatty liver disease: association with metabolic syndrome. Entropy 2018; 20(12):893.

Breslavets A, Breslavets M, Shear NH. Quantification of randomness (entropy) as a clinical tool to assess the severity of skin disease. Med Hypotheses 2019;132:109311.

Kalloo J, Priscilla S, Puttanna A. Pharmacological management of type 2 diabetes: clinical considerations and future perspectives. M&TOD 2023; 3(2):7.

Chandrasekaran P, Weiskirchen R. Diabetes mellitus and heart disease. M&TOD 2024; 4(2):18.

Clemente-Suarez VJ, Martin-Rodriguez A, Redondo-Florez L, Lopez-Mora C, Yanez-Sepulveda R, Tornero-Aguilera JF. New insights and potential therapeutic interventions in metabolic diseases. Int J Mol Sci 2023; 24(13):10672.

Guerra JVS, Dias MMG, Brilhante A, Terra MF, Garcia-Arevalo M, Figueira ACM. Multifactorial basis and therapeutic strategies in metabolism-related diseases. Nutrients 2021; 13(8):2830.

Jiang J, Li H, Tang M, Lei L, Li HY, Dong B, et al. Upregulation of hepatic glutathione s-transferase alpha 1 ameliorates metabolic dysfunction-associated steatosis by degrading fatty acid binding protein 1. Int J Mol Sci 2024; 25(10):5086.

Ma X, Feng D, Lu Y, Sun N, Wang J, Xu L. Editorial: novel strategies targeting obesity and metabolic diseases, volume II. Front Physiol 2024;15:1342943.

Pinheiro MM, Pinheiro FMM, Garo ML, Pastore D, Pacifici F, Ricordi C, et al. Prevention and treatment of type 1 diabetes: in search of the ideal combination therapy targeting multiple immunometabolic pathways. M&TOD 2024; 4(3):19.

Li H, Liu NN, Li JR, Dong B, Wang MX, Tan JL, et al. Combined use of bicyclol and berberine alleviates mouse nonalcoholic fatty liver disease. Front Pharmacol 2022;13:843872.

Li H, Liu NN, Peng ZG. Effect of bicyclol on blood biomarkers of NAFLD: a systematic review and meta-analysis. BMJ Open 2020; 10(12):e039700.

Zhu JY, Tang M, Li H, Shi YL, Li YM, Li YH, et al. Design, synthesis and triglyceride-lowering activity of tricyclic matrine derivatives for the intervention of non-alcoholic fatty liver disease. Bioorg Chem 2024;142:106925.

Li R, Ren G, Han YX, Wang LL, Jiang JD. Searching for head goose molecules as drug target. Chin Med Biotechnol 2024; 19(6):489-92 [Chinese].

Wang X, Li H, Li J, Lei L, Xu J, Sun H, et al. Berberine dissociates mitochondrial complex I by SIRT3-dependent deacetylation of NDUFS1 to improve hepatocellular glucose and lipid metabolism. Sci China Life Sci 2025; 68(9):2676-96.

Ning Y, Dou X, Wang Z, Shi K, Wang Z, Ding C, et al. SIRT3: a potential therapeutic target for liver fibrosis. Pharmacol Ther 2024;257:108639.

Wang Y, He J, Liao M, Hu M, Li W, Ouyang H, et al. An overview of sirtuins as potential therapeutic target: structure, function and modulators. Eur J Med Chem 2019;161:16148-77.

Wu QJ, Zhang TN, Chen HH, Yu XF, Lv JL, Liu YY, et al. The sirtuin family in health and disease. Signal Transduct Target Ther 2022; 7(1):402.

Tao L, Zhou Y, Luo Y, Qiu J, Xiao Y, Zou J, et al. Epigenetic regulation in cancer therapy: from mechanisms to clinical advances. MedComm Oncol 2024; 3(1):e59.

Erion DM, Yonemitsu S, Nie Y, Nagai Y, Gillum MP, Hsiao JJ, et al. Sirt1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats. Proc Natl Acad Sci USA 2009; 106(27):11288-93.

Cornejo PJ, Vergoni B, Ohanna M, Angot B, Gonzalez T, Jager J, et al. The stress-responsive microRNA-34a alters insulin signaling and actions in adipocytes through induction of the tyrosine phosphatase PTP1B. Cells 2022; 11(16):2581.

Watanabe H, Inaba Y, Kimura K, Matsumoto M, Kaneko S, Kasuga M, et al. SIRT2 facilitates hepatic glucose uptake by deacetylating glucokinase regulatory protein. Nat Commun 2018; 9(1):30.

Betsinger CN, Cristea IM. Mitochondrial function, metabolic regulation, and human disease viewed through the prism of sirtuin 4 (SIRT4) functions. J Proteome Res 2019; 18(5):1929-38.

Han Y, Zhou S, Coetzee S, Chen A. SIRT4 and its roles in energy and redox metabolism in health, disease and during exercise. Front Physiol 2019;10:1006.

Ma Y, Fei X. SIRT5 regulates pancreatic beta-cell proliferation and insulin secretion in type 2 diabetes. Exp Ther Med 2018; 16(2):1417-25.

Yamagata K, Mizumoto T, Yoshizawa T. The emerging role of SIRT7 in glucose and lipid metabolism. Cells 2023; 13(1):48.

Li H, Xu M, Lee J, He C, Xie Z. Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice. Am J Physiol Endocrinol Metab 2012; 303(10):E1234-44.

Li S, Guo L. The role of sirtuin 2 in liver—an extensive and complex biological process. Life Sci 2024;339:122431.

Zhang T, Liu J, Tong Q, Lin L. SIRT 3 acts as a positive autophagy regulator to promote lipid mobilization in adipocytes via activating AMPK. Int J Mol Sci 2020; 21(2):372.

Nasrin N, Wu X, Fortier E, Feng Y, Bare OC, Chen S, et al. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. J Biol Chem 2010; 285(42):31995-2002.

Laurent G, de Boer VC, Finley LW, Sweeney M, Lu H, Schug TT, et al. SIRT4 represses peroxisome proliferator-activated receptor alpha activity to suppress hepatic fat oxidation. Mol Cell Biol 2013; 33(22):4552-61.

Wang CH, Wei YH. Roles of mitochondrial sirtuins in mitochondrial function, redox homeostasis, insulin resistance and type 2 diabetes. Int J Mol Sci 2020; 21(15):5266.

Fabbrizi E, Fiorentino F, Carafa V, Altucci L, Mai A, Rotili D. Emerging roles of SIRT5 in metabolism, cancer, and SARS-CoV-2 infection. Cells 2023; 12(6):852.

Du Y, Hu H, Qu S, Wang J, Hua C, Zhang J, et al. SIRT5 deacylates metabolism-related proteins and attenuates hepatic steatosis in ob/ob mice. EBioMedicine 2018;36:347-57.

Choubey SK, Prabhu D, Nachiappan M, Biswal J, Jeyakanthan J. Molecular modeling, dynamics studies and density functional theory approaches to identify potential inhibitors of SIRT4 protein from Homo sapiens: a novel target for the treatment of type 2 diabetes. J Biomol Struct Dyn 2017; 35(15):3316-29.

Tang Q, Liu Q, Yang X, Wu T, Huang C, Zhang J, et al. Sirtuin 6 supra-physiological overexpression in hypothalamic pro-opiomelanocortin neurons promotes obesity via the hypothalamus-adipose axis. FASEB J 2021; 35(3):e21408.

Raj S, Dsouza LA, Singh SP, Kanwal A. SIRT 6 deacetylase: a potential key regulator in the prevention of obesity, diabetes and neurodegenerative disease. Front Pharmacol 2020;11:598326.

Chalkiadaki A, Guarente L. The multifaceted functions of sirtuins in cancer. Nat Rev Cancer 2015; 15(10):608-24.

Ouyang S, Zhang Q, Lou L, Zhu K, Li Z, Liu P, et al. The double-edged sword of SIRT3 in cancer and its therapeutic applications. Front Pharmacol 2022;13:871560.

Zhong X, Huang M, Kim HG, Zhang Y, Chowdhury K, Cai W, et al. SIRT 6 protects against liver fibrosis by deacetylation and suppression of Smad3 in hepatic stellate cells. Cell Mol Gastroenterol Hepatol 2020; 10(2):341-64.

Zhu C, Huang M, Kim HG, Chowdhury K, Gao J, Liu S, et al. SIRT6 controls hepatic lipogenesis by suppressing LXR, ChREBP, and SREBP1. Biochim Biophys Acta Mol Basis Dis 2021; 1867(12):166249.

Arora A, Dey CS. SIRT 2 regulates insulin sensitivity in insulin resistant neuronal cells. Biochem Biophys Res Commun 2016; 474(4):747-52.

Yang W, Nagasawa K, Munch C, Xu Y, Satterstrom K, Jeong S, et al. Mitochondrial sirtuin network reveals dynamic SIRT3-dependent deacetylation in response to membrane depolarization. Cell 2016; 167(4):985-1000.e21.

Zhang J, Xiang H, Liu J, Chen Y, He RR, Liu B. Mitochondrial sirtuin 3: new emerging biological function and therapeutic target. Theranostics 2020; 10(18):8315-42.

Murugasamy K, Munjal A, Sundaresan NR. Emerging roles of SIRT3 in cardiac metabolism. Front Cardiovasc Med 2022;9:850340.

Zhao Y, Li J, Ma A, Wang Z, Ni Y, Wu D, et al. Irisin alleviates hepatic steatosis by activating the autophagic SIRT 3 pathway. Chin Med J 2025;10:1097.

Lantier L, Williams AS, Williams IM, Yang KK, Bracy DP, Goelzer M, et al. SIRT3 is crucial for maintaining skeletal muscle insulin action and protects against severe insulin resistance in high-fat-fed mice. Diabetes 2015; 64(9):3081-92.

Yu J, Auwerx J. The role of sirtuins in the control of metabolic homeostasis. Ann N Y Acad Sci 2009;1173:E10-9.

Lambona C, Zwergel C, Valente S, Mai A. SIRT 3 activation a promise in drug development? New insights into SIRT3 biology and its implications on the drug discovery process. J Med Chem 2024; 67(3):1662-89.

Jing E, Emanuelli B, Hirschey MD, Boucher J, Lee KY, Lombard D, et al. Sirtuin-3 (SIRT3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production. Proc Natl Acad Sci USA 2011; 108(35):14608-13.

Jing E, O’Neill BT, Rardin MJ, Kleinridders A, Ilkeyeva OR, Ussar S, et al. SIRT3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes 2013; 62(10):3404-17.

Zhang Y, Wen P, Luo J, Ding H, Cao H, He W, et al. Sirtuin 3 regulates mitochondrial protein acetylation and metabolism in tubular epithelial cells during renal fibrosis. Cell Death Dis 2021; 12(9):847.

Zhang Q, Siyuan Z, Xing C, Ruxiu L. SIRT 3 regulates mitochondrial function: a promising star target for cardiovascular disease therapy. Biomed Pharmacother 2024;170:116004.

Carnevale I, Pellegrini L, D’Aquila P, Saladini S, Lococo E, Polletta L, et al. SIRT1-SIRT3 axis regulates cellular response to oxidative stress and etoposide. J Cell Physiol 2017; 232(7):1835-44.

Shen H, Qi X, Hu Y, Wang Y, Zhang J, Liu Z, et al. Targeting sirtuins for cancer therapy: epigenetics modifications and beyond. Theranostics 2024; 14(17):6726-67.

Xiong Y, Wang L, Wang S, Wang M, Zhao J, Zhang Z, et al. SIRT 3 deacetylates and promotes degradation of P53 in PTEN-defective non-small cell lung cancer. J Cancer Res Clin Oncol 2018; 144(2):189-98.

Wang S, Zhang J, Deng X, Zhao Y, Xu K. Advances in characterization of SIRT3 deacetylation targets in mitochondrial function. Biochimie 2020;179:1791-11713.

Rui L. Energy metabolism in the liver. Compr Physiol 2014; 4(1):177-97.

Shimazu T, Hirschey MD, Hua L, Dittenhafer-Reed KE, Schwer B, Lombard DB, et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab 2010; 12(6):654-61.

Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, et al. A role for the mitochondrial deacetylase Sirt 3 in regulating energy homeostasis. Proc Natl Acad Sci USA 2008; 105(38):14447-52.

Nassir F, Arndt JJ, Johnson SA, Ibdah JA. Regulation of mitochondrial trifunctional protein modulates nonalcoholic fatty liver disease in mice. J Lipid Res 2018; 59(6):967-73.

Zhang Y, Bharathi SS, Rardin MJ, Uppala R, Verdin E, Gibson BW, et al. SIRT3 and SIRT5 regulate the enzyme activity and cardiolipin binding of very long-chain acyl-CoA dehydrogenase. PLoS One 2015; 10(3):e0122297.

Lu Z, Chen Y, Aponte AM, Battaglia V, Gucek M, Sack MN. Prolonged fasting identifies heat shock protein 10 as a sirtuin 3 substrate: elucidating a new mechanism linking mitochondrial protein acetylation to fatty acid oxidation enzyme folding and function. J Biol Chem 2015; 290(4):2466-76.

Pham DV, Tilija Pun N, Park PH. Autophagy activation and SREBP-1 induction contribute to fatty acid metabolic reprogramming by leptin in breast cancer cells. Mol Oncol 2021; 15(2):657-78.

Li M, Li D, Wang HY, Zhang W, Zhuo Z, Guo H, et al. Leptin decreases Th17/Treg ratio to facilitate neuroblastoma via inhibiting long-chain fatty acid catabolism in tumor cells. OncoImmunology 2025; 14(1):2460281.

Hopkins TA, Dyck JR, Lopaschuk GD. AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart. Biochem Soc Trans 2003; 31(Pt 1):207-12.

Zhang YK, Qu YY, Lin Y, Wu XH, Chen HZ, Wang X, et al. Enoyl-CoA hydratase-1 regulates mTOR signaling and apoptosis by sensing nutrients. Nat Commun 2017; 8(1):464.

Pillai VB, Sundaresan NR, Kim G, Gupta M, Rajamohan SB, Pillai JB, et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem 2010; 285(5):3133-44.

Zhang HH, Ma XJ, Wu LN, Zhao YY, Zhang PY, Zhang YH, et al. SIRT1 attenuates high glucose-induced insulin resistance via reducing mitochondrial dysfunction in skeletal muscle cells. Exp Biol Med 2015; 240(5):557-65.

Yang Y, Cimen H, Han MJ, Shi T, Deng JH, Koc H, et al. NAD⁺-dependent deacetylase SIRT 3 regulates mitochondrial protein synthesis by deacetylation of the ribosomal protein MRPL10. J Biol Chem 2010; 285(10):7417-29.

Wang Y, Zhang X, Wang P, Shen Y, Yuan K, Li M, et al. SIRT3 overexpression alleviates hyperglycemia-induced vascular inflammation through regulating redox balance, cell survival, and AMPK-mediated mitochondrial homeostasis. J Recept Signal Transduct Res 2019; 39(4):341-9.

Shen Y, Wu Q, Shi J, Zhou S. Regulation of SIRT3 on mitochondrial functions and oxidative stress in Parkinson’s disease. Biomed Pharmacother 2020;132:110928.

Samant SA, Zhang HJ, Hong Z, Pillai VB, Sundaresan NR, Wolfgeher D, et al. SIRT 3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress. Mol Cell Biol 2014; 34(5):807-19.

Shen Y, Wang X, Nan N, Fu X, Zeng R, Yang Y, et al. SIRT3-mediated deacetylation of SDHA rescues mitochondrial bioenergetics contributing to neuroprotection in rotenone-induced PD models. Mol Neurobiol 2024; 61(7):4402-20.

Meng H, Yan WY, Lei YH, Wan Z, Hou YY, Sun LK, et al. SIRT3 regulation of mitochondrial quality control in neurodegenerative diseases. Front Aging Neurosci 2019;11:313.

Tseng AH, Shieh SS, Wang DL. SIRT 3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic Biol Med 2013;63:63222-34.

Ansari A, Rahman MS, Saha SK, Saikot FK, Deep A, Kim KH. Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease. Aging Cell 2017; 16(1):4-16.

Zhao WY, Zhang L, Sui MX, Zhu YH, Zeng L. Protective effects of sirtuin 3 in a murine model of sepsis-induced acute kidney injury. Sci Rep 2016; 6(1):33201.

Guo X, Yan F, Li J, Zhang C, Su H, Bu P. SIRT 3 ablation deteriorates obesity-related cardiac remodeling by modulating ROS-NF-kappaB-MCP-1 signaling pathway. J Cardiovasc Pharmacol 2020; 76(3):296-304.

Stuart JA, Aibueku O, Bagshaw O, Moradi F. Hypoxia inducible factors as mediators of reactive oxygen/nitrogen species homeostasis in physiological normoxia. Med Hypotheses 2019;129:109249.

Liu P, Huang G, Wei T, Gao J, Huang C, Sun M, et al. Sirtuin 3-induced macrophage autophagy in regulating NLRP 3 inflammasome activation. Biochim Biophys Acta Mol Basis Dis 2018; 1864(3):764-77.

Cao M, Zhao Q, Sun X, Qian H, Lyu S, Chen R, et al. Sirtuin 3: emerging therapeutic target for cardiovascular diseases. Free Radic Biol Med 2022;180:63-74.

Lu T, Ding L, Zheng X, Li Y, Wei W, Liu W, et al. Alisol a exerts neuroprotective effects against HFD-induced pathological brain aging via the SIRT3-NF-kappaB/MAPK pathway. Mol Neurobiol 2024; 61(2):753-71.

Koyama T, Kume S, Koya D, Araki S, Isshiki K, Chin-Kanasaki M, et al. SIRT3 attenuates palmitate-induced ROS production and inflammation in proximal tubular cells. Free Radic Biol Med 2011; 51(6):1258-67.

Peng F, Liao M, Jin W, Liu W, Li Z, Fan Z, et al. 2-APQC, a small-molecule activator of sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis. Signal Transduct Target Ther 2024; 9(1):133.

Song Y, Shi J, Wu Y, Han C, Zou J, Shi Y, et al. Metformin ameliorates insulin resistance in L6 rat skeletal muscle cells through upregulation of SIRT3. Chin Med J 2014; 127(8):1523-9.

Du Y, Zhang J, Fang F, Wei X, Zhang H, Tan H, et al. Metformin ameliorates hypoxia/reoxygenation-induced cardiomyocyte apoptosis based on the SIRT3 signaling pathway. Gene 2017;626:182-8.

Hu D, Xie F, Xiao Y, Lu C, Zhong J, Huang D, et al. Metformin: a potential candidate for targeting aging mechanisms. Aging Dis 2021; 12(2):480-93.

Yang K, Pei L, Zhou S, Tao L, Zhu Y. Metformin attenuates H₂O₂-induced osteoblast apoptosis by regulating SIRT3 via the PI3K/AKT pathway. Exp Ther Med 2021; 22(5):1316.

Diaz-Morales N, Rovira-Llopis S, Banuls C, Lopez-Domenech S, Escribano-Lopez I, Veses S, et al. Does metformin protect diabetic patients from oxidative stress and leukocyte-endothelium interactions? Antioxid Redox Signal 2017; 27(17):1439-45.

Xu X, Zhu XP, Bai JY, Xia P, Li Y, Lu Y, et al. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3. FASEB J 2019; 33(6):7289-300.

Li D, Yang C, Zhu JZ, Lopez E, Zhang T, Tong Q, et al. Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3. Acta Pharmacol Sin 2022; 43(5):1285-98.

Bijak M. Silybin, a major bioactive component of milk thistle (Silybum marianum l. gaernt.)-chemistry, bioavailability, and metabolism. Molecules 2017; 22(11):1942.

Li Y, Ye Z, Lai W, Rao J, Huang W, Zhang X, et al. Activation of sirtuin 3 by silybin attenuates mitochondrial dysfunction in cisplatin-induced acute kidney injury. Front Pharmacol 2017;8:178.

Zhou X, Chen M, Zeng X, Yang J, Deng H, Yi L, et al. Resveratrol regulates mitochondrial reactive oxygen species homeostasis through SIRT3 signaling pathway in human vascular endothelial cells. Cell Death Dis 2014; 5(12):e1576.

Desquiret-Dumas V, Gueguen N, Leman G, Baron S, Nivet-Antoine V, Chupin S, et al. Resveratrol induces a mitochondrial complex I-dependent increase in NADH oxidation responsible for sirtuin activation in liver cells. J Biol Chem 2013; 288(51):36662-75.

Lu J, Zhang H, Chen X, Zou Y, Li J, Wang L, et al. A small molecule activator of SIRT3 promotes deacetylation and activation of manganese superoxide dismutase. Free Radic Biol Med 2017;112:287-97.

Gertz M, Nguyen GT, Fischer F, Suenkel B, Schlicker C, Franzel B, et al. A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One 2012; 7(11):e49761.

Xu H, Gan C, Gao Z, Huang Y, Wu S, Zhang D, et al. Caffeine targets SIRT 3 to enhance SOD2 activity in mitochondria. Front Cell Dev Biol 2020;8:822.

Zhang SJ, Li YF, Wang GE, Tan RR, Tsoi B, Mao GW, et al. Caffeine ameliorates high energy diet-induced hepatic steatosis: sirtuin 3 acts as a bridge in the lipid metabolism pathway. Food Funct 2015; 6(8):2578-87.

Wu J, Yang Y, Gao Y, Wang Z, Ma J. Melatonin attenuates anoxia/reoxygenation injury by inhibiting excessive mitophagy through the MT2/SIRT3/FOXO3a signaling pathway in H9c2 cells. Drug Des Devel Ther 2020;14:2047-60.

Akbari M, Ostadmohammadi V, Tabrizi R, Lankarani KB, Heydari ST, Amirani E, et al. The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials. Inflammopharmacology 2018; 26(4):899-907.

Wang Z, Cao Z, Yue Z, Yang Z. Research progress of dihydromyricetin in the treatment of diabetes mellitus. Front Endocrinol 2023;14:1216907.

Zhou J, Yue J, Yao Y, Hou P, Zhang T, Zhang Q, et al. Dihydromyricetin protects intestinal barrier integrity by promoting IL-22 expression in ILC3s through the AMPK/SIRT3/STAT3 signaling pathway. Nutrients 2023; 15(2):355.

Hua YY, Zhang Y, Gong WW, Ding Y, Shen JR, Li H, et al. Dihydromyricetin improves endothelial dysfunction in diabetic mice via oxidative stress inhibition in a SIRT3-dependent manner. Int J Mol Sci 2020; 21(18):6699.

Zhou J, Hou P, Yao Y, Yue J, Zhang Q, Yi L, et al. Dihydromyricetin improves high-fat diet-induced hyperglycemia through ILC3 activation via a SIRT3-dependent mechanism. Mol Nutr Food Res 2022; 66(16):e2101093.

Chen Y, Zheng Y, Chen R, Shen J, Zhang S, Gu Y, et al. Dihydromyricetin attenuates diabetic cardiomyopathy by inhibiting oxidative stress, inflammation and necroptosis via sirtuin 3 activation. Antioxidants 2023; 12(1):200.

Sun J, Fu X, Liu Y, Wang Y, Huo B, Guo Y, et al. Hypoglycemic effect and mechanism of honokiol on type 2 diabetic mice. Drug Des Devel Ther 2015;9:6327-42.

Pillai VB, Kanwal A, Fang YH, Sharp WW, Samant S, Arbiser J, et al. Honokiol, an activator of sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget 2017; 8(21):34082-98.

Pillai VB, Samant S, Sundaresan NR, Raghuraman H, Kim G, Bonner MY, et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial SIRT3. Nat Commun 2015; 6(1):6656.

Wang J, Nisar M, Huang C, Pan X, Lin D, Zheng G, et al. Small molecule natural compound agonist of SIRT3 as a therapeutic target for the treatment of intervertebral disc degeneration. Exp Mol Med 2018; 50(11):1-14.

Zhao K, Zhou Y, Qiao C, Ni T, Li Z, Wang X, et al. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in WT-p53 cancer cells. J Hematol Oncol 2015; 8(1):41.

Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, Hui H, et al. Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis 2013; 4(4):e601.

Cai T, Xu X, Dong L, Liang S, Xin M, Wang T, et al. Oroxin A from Oroxylum indicum improves disordered lipid metabolism by inhibiting SREBPs in oleic acid-induced HepG2 cells and high-fat diet-fed non-insulin-resistant rats. Heliyon 2024; 10(7):e29168.

Fan D, Yang Z, Liu FY, Jin YG, Zhang N, Ni J, et al. Sesamin protects against cardiac remodeling via SIRT3/ROS pathway. Cell Physiol Biochem 2017; 44(6):2212-27.

Guo R, Liu N, Liu H, Zhang J, Zhang H, Wang Y, et al. High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin Pills to restrain cardiomyocyte hypertrophy via activating SIRT3. Phytomedicine 2020;68:153171.

Wang Z, Li Y, Wang Y, Zhao K, Chi Y, Wang B. Pyrroloquinoline quinine protects HK-2 cells against high glucose-induced oxidative stress and apoptosis through Sirt3 and PI3K/Akt/FOXO3a signaling pathway. Biochem Biophys Res Commun 2019; 508(2):398-404.

Wang X, Deng Q, Hou J, Pasunooti KK, Bermea K, Li K, et al. Editorial: design of novel inhibitors for ischemia/reperfusion injury targeting ferroptosis. Front Pharmacol 2024;15:1475526.

Li ZY, Lu GQ, Lu J, Wang PX, Zhang XL, Zou Y, et al. SZC-6, a small-molecule activator of SIRT3, attenuates cardiac hypertrophy in mice. Acta Pharmacol Sin 2023; 44(3):546-60.

Hor JH, Santosa MM, Lim VJW, Ho BX, Taylor A, Khong ZJ, et al. ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT 3 activation. Cell Death Differ 2021; 28(4):1379-97.

Zhang J, Zou L, Shi D, Liu J, Zhang J, Zhao R, et al. Structure-guided design of a small-molecule activator of sirtuin-3 that modulates autophagy in triple negative breast cancer. J Med Chem 2021; 64(19):14192-216.

Bursch KL, Goetz CJ, Smith BC. Current trends in sirtuin activator and inhibitor development. Molecules 2024; 29(5):1185.

Suenkel B, Valente S, Zwergel C, Weiss S, Di Bello E, Fioravanti R, et al. Potent and specific activators for mitochondrial sirtuins SIRT3 and SIRT5. J Med Chem 2022; 65(20):14015-31.

Bi T, Cui Y, Liu S, Yu H, Qiu W, Hou KQ, et al. Ligand-enabled Pd-catalyzed sp₃ C-H macrocyclization: synthesis and evaluation of macrocyclic sulfonamide for the treatment of Parkinson’s disease. Angew Chem Int Ed 2024; 63(45):e202412296.

Zhang D, Zhang J, Wu C, Xiao Y, Ji L, Hu J, et al. Unraveling small molecule-mediated sirtuin 3 activation at a distinct binding site for cardioprotective therapies. ACS Cent Sci 2025; 11(5):704-18.

Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 2018; 108(2):343-53.

Zhou AJ, Xiong ZE, Wang L, Chen XX, Wang ZP, Zhang YD, et al. Long-term administration of nicotinamide mononucleotide mitigates high-fat-diet-induced physiological decline in aging mice. J Nutr 2025; 155(1):237-49.

Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021; 372(6547):1224-9.

Abdellatif M, Trummer-Herbst V, Koser F, Durand S, Adao R, Vasques-Novoa F, et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci Transl Med 2021; 13(580):eabd7064.

Shi W, Hegeman MA, van Dartel DAM, Tang J, Suarez M, Swarts H, et al. Effects of a wide range of dietary nicotinamide riboside (NR) concentrations on metabolic flexibility and white adipose tissue (WAT) of mice fed a mildly obesogenic diet. Mol Nutr Food Res 2017; 61(8):1600878.

Otto M, Breinholt J, Westergaard N. Metformin inhibits glycogen synthesis and gluconeogenesis in cultured rat hepatocytes. Diabetes Obes Metab 2003; 5(3):189-94.

Song HP, Zhang H, Hu R, Xiao HH, Guo H, Yuan WH, et al. A strategy to discover lead chemome from traditional Chinese medicines based on natural chromatogram-effect correlation (NCEC) and natural structure-effect correlation (NSEC): Mahonia bealei and Mahonia fortunei as a case study. J Chromatogr B Analyt Technol Biomed Life Sci 2021;1181:122922.

Zappavigna S, Vanacore D, Lama S, Potenza N, Russo A, Ferranti P, et al. Silybin-induced apoptosis occurs in parallel to the increase of ceramides synthesis and miRNAs secretion in human hepatocarcinoma cells. Int J Mol Sci 2019; 20(9):2190.

Wang G, Guo X, Chen H, Lin T, Xu Y, Chen Q, et al. A resveratrol analog, phoyunbene B, induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. Bioorg Med Chem Lett 2012; 22(5):2114-8.

Zhao Y, Ren J, Hillier J, Lu W, Jones EY. Caffeine inhibits Notum activity by binding at the catalytic pocket. Commun Biol 2020; 3(1):555.

Zhai M, Li B, Duan W, Jing L, Zhang B, Zhang M, et al. Melatonin ameliorates myocardial ischemia reperfusion injury through SIRT3-dependent regulation of oxidative stress and apoptosis. J Pineal Res 2017; 63(2):e12419.

Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernandez-Vazquez G. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res 2012; 52(2):203-10.

Carocci A, Catalano A, Bruno C, Lovece A, Roselli MG, Cavalluzzi MM, et al. N-(Phenoxyalkyl)amides as MT(1) and MT(2) ligands: antioxidant properties and inhibition of Ca₂₊/CaM-dependent kinase II. Bioorg Med Chem 2013; 21(4):847-51.

Kim CS, Bae M, Oh J, Subedi L, Suh WS, Choi SZ, et al. Anti-neurodegenerative biflavonoid glycosides from impatiens balsamina. J Nat Prod 2017; 80(2):471-8.

Lin D, Yan Z, Chen A, Ye J, Hu A, Liu J, et al. Anti-proliferative activity and structure-activity relationship of honokiol derivatives. Bioorg Med Chem 2019; 27(16):3729-34.

Wei L, Zhou Y, Qiao C, Ni T, Li Z, You Q, et al. Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1alpha destabilization. Cell Death Dis 2015; 6(4):e1714.

Dai Q, Yin Q, Wei L, Zhou Y, Qiao C, Guo Y, et al. Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of hypoxia-inducible factor-1 in human hepatoma HepG2 cells. Mol Carcinog 2016; 55(8):1275-89.

Fu W, Wang J, Yu L, Zhao L, Lu N, You Q, et al. Synthesis and biological evaluation of 7-O-modified oroxylin A derivatives. Bioorg Med Chem Lett 2012; 22(2):1118-21.

Quang TH, Ngan NT, Minh CV, Kiem PV, Tai BH, Thao NP, et al. Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii. Bioorg Med Chem Lett 2012; 22(7):2527-33.

Toda S, Shirataki Y. Inhibitory effects of isoflavones in Sophora mooracrotiana on lipid peroxidation by superoxide. Pharm Biol 2002; 40(6):422-4.

Ji XY, Xue ST, Zhan YC, Shen JJ, Wu LT, Jin J, et al. Design, synthesis and antiproliferative activity of a novel class of indole-2-carboxylate derivatives. Eur J Med Chem 2014;83:409-18.

Devabattula G, Bakchi B, Sharma A, Panda B, Madhavi V, Godugu C. 7-Hydroxy-3-(4′-methoxyphenyl) coumarin (C12) attenuates bleomycin-induced acute lung injury and fibrosis through activation of SIRT3. Biochem Pharmacol 2025;232:116723.

Takahashi D, Oyunzul L, Onoue S, Ito Y, Uchida S, Simsek R, et al. Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives. Biol Pharm Bull 2008; 31(3):473-9.

Ahn J, Chae HS, Chin YW, Kim J. Alkaloids from aerial parts of Houttuynia cordata and their anti-inflammatory activity. Bioorg Med Chem Lett 2017; 27(12):2807-11.

Buler M, Aatsinki SM, Izzi V, Hakkola J. Metformin reduces hepatic expression of SIRT3, the mitochondrial deacetylase controlling energy metabolism. PLoS One 2012; 7(11):e49863.

Li H, Wang XK, Tang M, Lei L, Li JR, Sun H, et al. Bacteroides thetaiotaomicron ameliorates mouse hepatic steatosis through regulating gut microbial composition, gut-liver folate and unsaturated fatty acids metabolism. Gut Microbes 2024; 16(1):2304159.

Kong WJ, Vernieri C, Foiani M, Jiang JD. Berberine in the treatment of metabolism-related chronic diseases: a drug cloud (dCloud) effect to target multifactorial disorders. Pharmacol Ther 2020;209:107496.

Brandauer J, Vienberg SG, Andersen MA, Ringholm S, Risis S, Larsen PS, et al. AMP-activated protein kinase regulates nicotinamide phosphoribosyl transferase expression in skeletal muscle. J Physiol 2013; 591(20):5207-20.

Teodoro JS, Duarte FV, Gomes AP, Varela AT, Peixoto FM, Rolo AP, et al. Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SIRT 3 activation. Mitochondrion 2013; 13(6):637-46.

Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10(12):1344-51.

Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 2015;161:69-81.

Wong VW, Neff GW, Di Bisceglie AM, Bai R, Cheng J, Yu M, et al. HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clin Mol Hepatol 2025; 31(3):1071-83.

Ji L, Ma J, Ma Y, Cheng Z, Gan S, Yuan G, et al. Berberine ursodeoxycholate for the treatment of type 2 diabetes: a randomized clinical trial. JAMA Netw Open 2025; 8(3):e2462185.

Zhang B, Xu D, She L, Wang Z, Yang N, Sun R, et al. Silybin inhibits NLRP 3 inflammasome assembly through the NAD⁺/SIRT2 pathway in mice with nonalcoholic fatty liver disease. FASEB J 2018; 32(2):757-67.

Cai J, Zhu Y, Li X, Deng G, Han Y, Yuan F, et al. Liposomal silybin improves glucose and lipid metabolisms in type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease via AMPK/TGF-beta1/Smad signaling. Tohoku J Exp Med 2023; 261(4):257-65.

Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008; 7(8):1020-35.

Ning L, Rui X, Guorui L, Tinglv F, Donghang L, Chenzhen X, et al. A novel mechanism for the protection against acute lung injury by melatonin: mitochondrial quality control of lung epithelial cells is preserved through SIRT3-dependent deacetylation of SOD2. Cell Mol Life Sci 2022; 79(12):610.

Reiter RJ, Tan DX, Rosales-Corral S, Galano A, Jou MJ, Acuna-Castroviejo D. Melatonin mitigates mitochondrial meltdown: interactions with SIRT3. Int J Mol Sci 2018; 19(8):2439.

Song C, Peng W, Yin S, Zhao J, Fu B, Zhang J, et al. Melatonin improves age-induced fertility decline and attenuates ovarian mitochondrial oxidative stress in mice. Sci Rep 2016; 6(1):35165.

Yu L, Gong B, Duan W, Fan C, Zhang J, Li Z, et al. Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: role of AMPK-PGC-1alpha-SIRT3 signaling. Sci Rep 2017; 7(1):41337.

Andreani T, Cheng R, Elbadri K, Ferro C, Menezes T, Dos Santos MR, et al. Natural compounds-based nanomedicines for cancer treatment: future directions and challenges. Drug Deliv Transl Res 2024; 14(10):2845-916.

Trevino-Saldana N, Garcia-Rivas G. Regulation of sirtuin-mediated protein deacetylation by cardioprotective phytochemical. Oxid Med Cell Longev 2017; 2017(1):1750306.

Zhu R, Zeng G, Chen Y, Zhang Q, Liu B, Liu J, et al. Oroxylin A accelerates liver regeneration in CCl₄-induced acute liver injury mice. PLoS One 2013; 8(8):e71612.

Zhang J, Meruvu S, Bedi YS, Chau J, Arguelles A, Rucker R, et al. Pyrroloquinoline quinone increases the expression and activity of SIRT1 and-3 genes in HepG2 cells. Nutr Res 2015; 35(9):844-9.

Mai A, Valente S, Meade S, Carafa V, Tardugno M, Nebbioso A, et al. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J Med Chem 2009; 52(17):5496-504.

Zwergel C, Aventaggiato M, Garbo S, Di Bello E, Fassari B, Noce B, et al. Novel 1,4-dihydropyridines as specific binders and activators of SIRT3 impair cell viability and clonogenicity and downregulate hypoxia-induced targets in cancer cells. J Med Chem 2023; 66(14):9622-41.

Shen H, Ma W, Hu Y, Liu Y, Song Y, Fu L, et al. Mitochondrial sirtuins in cancer: a revisited review from molecular mechanisms to therapeutic strategies. Theranostics 2024; 14(7):2993-3013.

Wang YJ, Paneni F, Stein S, Matter CM. Modulating sirtuin biology and nicotinamide adenine diphosphate metabolism in cardiovascular disease-from bench to bedside. Front Physiol 2021;12:755060.

Yue Z, Ma Y, You J, Li Z, Ding Y, He P, et al. NMNAT 3 is involved in the protective effect of SIRT3 in Ang II-induced cardiac hypertrophy. Exp Cell Res 2016; 347(2):261-73.

Nadtochiy SM, Wang YT, Nehrke K, Munger J, Brookes PS. Cardioprotection by nicotinamide mononucleotide (NMN): involvement of glycolysis and acidic pH. J Mol Cell Cardiol 2018;121:155-62.

Alhazzazi TY, Kamarajan P, Xu Y, Ai T, Chen L, Verdin E, et al. A novel sirtuin-3 inhibitor, LC-0296, inhibits cell survival and proliferation, and promotes apoptosis of head and neck cancer cells. Anticancer Res 2016; 36(1):49-60.

Gorska-Ponikowska M, Kuban-Jankowska A, Eisler SA, Perricone U, Lo Bosco G, Barone G, et al. 2-Methoxyestradiol affects mitochondrial biogenesis pathway and succinate dehydrogenase complex flavoprotein subunit a in osteosarcoma cancer cells. Cancer Genom Proteom 2018; 15(1):73-89.

Sann KM, Rahman M, Thu MM. Immunotherapy for type 1 diabetes. M&TOD 2024; 4(4):37.

Desalegn H, Farias R, Hudson D, Idalsoaga F, Cabrera D, Diaz LA, et al. Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease. M&TOD 2024; 4(3):25.